journal cover

Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol

Transplantation Proceedings

Nov 3, 2004

T AndoS Teraoka

Download from

Publisher
PubMed

Abstract

We have performed ABO-incompatible (ABO-i) kidney transplantation (KT) to alleviate the severe organ shortage in our country. Induction therapy with basiliximab, a monoclonal anti-interleukin-2 receptor antibody, is known to be effective in reducing the incidence of acute rejection (AR)...read more

Mentioned in this Paper

Monoclonal Antibodies
Decreased Immunologic Activity [PE]
Chimeric Proteins, Recombinant
Blood Group H Type 1 Antigen
Mycophenolate mofetil
Cyclosporine
Graft Survival
Cyclosporine Measurement
Adrenal Cortex Hormones
Graft Rejection
Paper Details
References

Feeds With Similar Papers

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Graft Rejection

Graft rejection occurs when the donor's grafted tissue is rejected by the recipient's immune system, destroying the transplanted tissue. Discover the latest research on graft rejection here.

Immune Tolerance

Immune tolerance happens when the immune system is not responsive to a substance or organism and does not elicit an immune response. This is a normal physiological response for some antigens, especially when detecting self from non-self. This has been a potential area of therapy for some disorders. Here is the latest research on immune tolerance.

Related Papers

© 2020 Meta ULC. All rights reserved

Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol

Transplantation Proceedings

Nov 3, 2004

T AndoS Teraoka

PMID: 15518793

DOI: 10.1016/j.transproceed.2004.07.051

Abstract

We have performed ABO-incompatible (ABO-i) kidney transplantation (KT) to alleviate the severe organ shortage in our country. Induction therapy with basiliximab, a monoclonal anti-interleukin-2 receptor antibody, is known to be effective in reducing the incidence of acute rejection (AR)...read more

Mentioned in this Paper

Monoclonal Antibodies
Decreased Immunologic Activity [PE]
Chimeric Proteins, Recombinant
Blood Group H Type 1 Antigen
Mycophenolate mofetil
Cyclosporine
Graft Survival
Cyclosporine Measurement
Adrenal Cortex Hormones
Graft Rejection

Feeds With Similar Papers

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Graft Rejection

Graft rejection occurs when the donor's grafted tissue is rejected by the recipient's immune system, destroying the transplanted tissue. Discover the latest research on graft rejection here.

Related Papers

Journal of the American Chemical Society

Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier

Journal of the American Chemical SocietyNovember 5, 2008
Wei WeiZhe-Yu Shen

Download from

Publisher
PubMed
/papers/efficacy-of-basiliximab-induction-therapy-in-abo-i/15518793